| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | BRD-K84807411 | CTRPv2 | pan-cancer | AAC | -0.063 | 0.4 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | BRD-K29313308 | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.051 | 0.4 |
| mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | 0.043 | 0.4 |
| mRNA | BMS-708163 | GDSC1000 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | BRD-K90370028 | CTRPv2 | pan-cancer | AAC | -0.049 | 0.4 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.042 | 0.4 |